



Cardiac Transthyretin Amyloid (ATTR) Fellowship Competitive Grant Program - Request for Proposals (RFP)

Introduction

The International Society of Amyloidosis (ISA) and Pfizer are collaborating to offer a new competitive grant opportunity focused on supporting fellowships in Cardiac Transthyretin Amyloid (ATTR).

The mission of the International Society of Amyloidosis (ISA) is to promote research, education, clinical studies (including diagnosis and treatment), conferences and symposia on all aspects of amyloidosis worldwide.

The mission of Pfizer Global Medical Grants is to accelerate the translation of science into quality patient care through independent grants, partnerships, and collaborations. Pfizer Global Medical Grants supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

This Request for Proposals (RFP) is being issued by both organizations. An expert review panel will be selected by ISA and will make decisions on which proposals will receive funding. Grant funding will be provided directly from Pfizer.

Competitive Grant Program Eligibility

Geographic Scope	<ul style="list-style-type: none">• Global
Applicant Eligibility Criteria	<p>To be eligible:</p> <ul style="list-style-type: none">• Do <u>not</u> include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual.• Institutions with fellowship programs that include independent research and a strong mentoring program.<ul style="list-style-type: none">○ Examples of independent research include observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health.<ul style="list-style-type: none">▪ Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.).○ Examples of clinical training include educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions.

	<ul style="list-style-type: none"> • Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care. • No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Requirements

Date RFP Issued	<ul style="list-style-type: none"> • June 28, 2021
Clinical Area	<ul style="list-style-type: none"> • Cardiac Transthyretin Amyloid (ATTR).
Area of Interest Focus	<ul style="list-style-type: none"> • This is a program based (not project based) grant • It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of Cardiac Transthyretin Amyloid (ATTR). • There is funding to support 5 fellowships: 1 North America, 1 Latin America, 1 European Union, 1 Africa/Middle East and 1 Asia Pacific
Expected Approximate Monetary Range of Grant Applications	<ul style="list-style-type: none"> • Grant funding is available to support one fellow for a year at up to \$125,000. The budget may only include salary and support of the fellow benefits. • Grant funds cannot be used for overhead or indirect costs. • Funding will be awarded to the institution, not an individual. • Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care. • No aspect of the fellowship program budget can reflect a benefit to Pfizer’s business or a Pfizer asset.

Key Dates	<ul style="list-style-type: none"> • RFP release date: June 28, 2021 • Full Proposal Deadline: August 23, 2021 • Review of Full Proposals by Expert Review Panel: October 2021 • Anticipated Full Proposal Notification Date: November/December 2021 • Grants distributed in early 2022 following execution of fully signed Contract
How to Apply	<ul style="list-style-type: none"> • Please go to http://www.cybergrants.com/pfizer/GMGFellowship and sign in. First-time users should click “Create your password”. • Select the following Competitive Grant Program Name: 2021 RD G - ATTR Fellowship ISA Global • Requirements for submission: <ul style="list-style-type: none"> • Complete all required sections of the online application • You must upload a Proposal. Click here to access the template for the Proposal. • If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.
Questions:	<ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com), with the subject line “ATTR Global Fellowship.” • Please click here to view Frequently Asked Questions regarding the Competitive Grant Program
Review and Approval Process	<ul style="list-style-type: none"> • A specific grant program RFP uses an expert review panel (ERP) to make final grant decisions. • The panel will be selected by ISA and will be comprised of professionals from the medical community with advanced degrees and expertise in ATTR.
Mechanism by which Applicants will be Notified:	<ul style="list-style-type: none"> • All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period.